Kidswell Bio Corporation · TSE:4584
Kidswell Bio — Q3 FY2021 Earnings Presentation
13 slides from Kidswell Bio's earnings presentation, Feb 4, 2022
Slide 1: Financial Results for 3Q/FY2021
証券ｺｰﾄﾞ:4584 Financial Results for 3Q/FY2021 (Fiscal Year Ending March 31, 2022) February 4, 2022 Kidswell Bio Corporation
Slide 2: Cautionary Statement
Cautionary Statement This information material is provided for understanding Kidswell Bio Corporation (“KWB”), not for soliciting investment in KWB shares. Information provided in this material may contain so-called “forward- looking statements.” These statements are based on current expectations, f
Slide 3: Business and Financial Highlights in 3Q/FY2021
Business and Financial Highlights in 3Q/FY2021 3
Slide 4: Overview of Financial and Business Highlights
Overview of Financial and Business Highlights Financial Highlights ◆ Financial Highlights in 3Q/FY2021 Sales results were in line with the forecast.（started launching Ranibizumab biosimilar） R&D is steadily proceeding by realized business alliances Strengthened financial stability by the proce
Slide 5: Consolidated Financial Results in 3Q/FY2021
Consolidated Financial Results in 3Q/FY2021 Consolidated income statement Unit:thousands yen Forecasts for FY2021 Results for Subject Highlights 3Q/FY2020 Results for Forecasts 3Q/FY2021 Profits from GBS-001 and GBS-011GBS-001、011 exceeded the plan Recorded drug substance sales related to the ma
Slide 6: Consolidated Financial Results for 3Q/FY2021
Consolidated Financial Results for 3Q/FY2021 Recorded cash proceeds of 500 million yen from investment securities sales Consolidated balance sheet Driving KWB’s mid-term business strategy with increasing sales revenue of GBS-007 and execution of outstanding warrants (in thousand Assets (in thousand
Slide 7: Updates of Mid-Term Strategic Plan From FY2021 to FY2025
Updates of Mid-Term Strategic Plan From FY2021 to FY2025 7
Slide 8: Key Updates in Mid-Term Strategic Plan
Key Updates in Mid-Term Strategic Plan Key updates in 3Q/FY2021 UPDATE! Business Alliance Agreement with Metcela Expansion and further Licensing SHED CSC development in regenerative -out JRM-001 medicine field of KWB and Metcela UPDATE! Regenerative Biosimilars Development Agreement R&D Medicine New
Slide 9: GBS-007: Launched new BS as the first BS in the ophthalmology field
GBS-007: Launched new BS as the first BS in the ophthalmology field Highlights GBS-007 launched by Senju Pharmaceutical Co., Ltd. from Dec. 9, 2021. Included the sales in the 3Q Expecting acquiring market share in existing products market as the first BS in the ophthalmology field. Adding indi
Slide 10: Key of MCB in cell medicines
Key of MCB in cell medicines ■ SHED: Research & Development Selected of Basic research Licensing -out Clinical Manufacturing and marketing Launch to the target diseases Non-clinical study alliance trial approval market Major target diseases Effectiveness in Spinal cord injury multiple pipelines Esta
Slide 11: New drug discovery: Collaborative development with NanoCarrier and BMS
Designer cell development -New drug discovery－ Shifting development trends in domestic & overseas: designer cell for radical treatment 1900~2000 2000~2020 2020～ Small Antibody drugs Next generation molecule medicine Designer Cell Modality of Cell Regenerative Medicine therapy Nucleic acid medicine A
Slide 12: Business Alliance with Metcela
Business Alliance with Metcela Highlight Metcela has been developing regenerative medicine for chronic heart failure. Combining management resources, knowledge and technologies and accelerating development in the regenerative medicine field of KWB and Metcela Expecting new pipelines in regener
Slide 13: KIDS WELL, ALL WELL
Kidswell.Bio KIDS WELL, ALL WELL Kidswell Bio Corporation